What is the 13F Pro Quality Score for TCRT?

13F Pro ranks Alaunos Therapeutics, Inc. (TCRT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TCRT's current score at https://13fpro.ai/company/TCRT (free sign-up required for the full ranking).

Which hedge funds own the most TCRT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of TCRT include BlackRock,, GEODE CAPITAL MANAGEMENT,, VANGUARD FIDUCIARY CO. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/TCRT as soon as new 13F filings post.

Where does 13F Pro source TCRT data?

All Alaunos Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Alaunos Therapeutics, Inc. files with the SEC under CIK 1107421. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TCRT in?

Alaunos Therapeutics, Inc. (TCRT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TCRT research updated on 13F Pro?

TCRT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Alaunos Therapeutics, Inc.(TCRT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1107421 TCRT stock profile & AI dashboard →

13F Pro Quality Score

5.5/100

Rank #2,953 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why TCRT Scores 6/100

exact factor attribution · 2026-09-11

TCRT's composite is held back by revenue growth and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings quality

-1.3 pts

37th pct

Institutional flow

-1.7 pts

16th pct

Earnings growth

-2.2 pts

5th pct

Shareholder dilution

-2.5 pts

0th pct

Capital efficiency

-4.7 pts

3th pct

Profitability

-7.4 pts

0th pct

Free cash flow

-7.5 pts

0th pct

Scale

-7.5 pts

0th pct

Revenue growth

-9.8 pts

1th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

TCRT Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Alaunos Therapeutics, Inc. (TCRT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TCRT at 5.5/100 on a 32-signal composite quality model, placing it at rank #2,953 of 2,962 stocks — the bottom half of the AI-ranked universe. Top institutional holders of TCRT by reported 13-F value include BlackRock, GEODE CAPITAL MANAGEMENT, VANGUARD FIDUCIARY, based on the most recent SEC filings. TCRT trades on the Nasdaq exchange and files with the SEC under CIK 1107421. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TCRT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Alaunos Therapeutics, Inc. directly from SEC EDGAR. Alaunos Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 6 and 27 since 2026, currently 5.5 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.

Revenue

Q2 2026

$0.00

Net Income

Q2 2026

$-952.0K

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-50.0% YoY

$5.0KFY 2025

FY22 $2.9MFY23 $5.0KFY24 $10.0KFY25 $5.0K

Net Income

+10.8% YoY

$-4.2MFY 2025

FY22 $-37.7MFY23 $-4.7MFY24 $-4.7MFY25 $-4.2M

Operating Income

+12.2% YoY

$-4.2MFY 2025

FY22 $-35.1MFY23 $-34.3MFY24 $-4.8MFY25 $-4.2M

EPS (Diluted)

+24.7% YoY

$-2.20FY 2025

FY22 $-0.02FY23 $-2.20FY24 $-2.92FY25 $-2.20

Total Assets

+7.7% YoY

$3.0MFY 2025

FY22 $64.9MFY23 $8.3MFY24 $2.8MFY25 $3.0M

Total Debt

—FY 2025

FY22 $16.8MFY23 $0.00FY24 $0.00FY25 —

Op. Cash Flow

+42.3% YoY

$-2.9MFY 2025

FY22 $-29.2MFY23 $-30.1MFY24 $-5.0MFY25 $-2.9M

Free Cash Flow

+40.3% YoY

$-3.0MFY 2025

FY22 $-29.4MFY23 $-30.3MFY24 $-5.0MFY25 $-3.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$5.0K -50.0%	$10.0K +100.0%	$5.0K -99.8%	$2.9M +634.2%	$398.0K	$0.00
Net Income	$-4.2M +10.8%	$-4.7M +0.0%	$-4.7M +87.6%	$-37.7M +52.1%	$-78.8M +1.5%	$-80.0M
Operating Income	$-4.2M +12.2%	$-4.8M +86.0%	$-34.3M +2.4%	$-35.1M +54.7%	$-77.5M +3.5%	$-80.4M
EPS (Diluted)	$-2.20 +24.7%	$-2.92 -32.9%	$-2.20 -12526.4%	$-0.02 -596.0%	$-0.00 +0.0%	$-0.00
Total Assets	$3.0M +7.7%	$2.8M -66.7%	$8.3M -87.3%	$64.9M -31.5%	$94.9M -35.2%	$146.3M
Total Debt	—	$0.00	$0.00 -100.0%	$16.8M -30.5%	$24.1M	$0.00
Operating Cash Flow	$-2.9M +42.3%	$-5.0M +83.5%	$-30.1M -3.1%	$-29.2M +52.4%	$-61.5M -7.8%	$-57.0M
Free Cash Flow	$-3.0M +40.3%	$-5.0M +83.6%	$-30.3M -3.0%	$-29.4M +54.5%	$-64.8M +3.0%	$-66.8M

Get alerted when TCRT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Alaunos Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TCRT

BlackRock, Inc.
$48.3K21,353 sh
GEODE CAPITAL MANAGEMENT, LLC
$43.8K19,356 sh
VANGUARD FIDUCIARY TRUST CO
$35.0K15,497 sh
VANGUARD CAPITAL MANAGEMENT LLC
$31.8K14,063 sh
CITADEL ADVISORS LLC
$26.8K11,870 sh
OSAIC HOLDINGS, INC.
$3.9K1,731 sh
Tower Research Capital LLC (TRC)
$3.7K1,621 sh
SRS Capital Advisors, Inc.
$2.7K1,216 sh
UBS Group AG
$2.2K992 sh
MORGAN STANLEY
$1.9K836 sh

Fund	Value	Shares
BlackRock, Inc.	$48.3K	21,353
GEODE CAPITAL MANAGEMENT, LLC	$43.8K	19,356
VANGUARD FIDUCIARY TRUST CO	$35.0K	15,497
VANGUARD CAPITAL MANAGEMENT LLC	$31.8K	14,063
CITADEL ADVISORS LLC	$26.8K	11,870
OSAIC HOLDINGS, INC.	$3.9K	1,731
Tower Research Capital LLC (TRC)	$3.7K	1,621
SRS Capital Advisors, Inc.	$2.7K	1,216
UBS Group AG	$2.2K	992
MORGAN STANLEY	$1.9K	836

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TCRT on your watchlist

Track score changes the day Alaunos Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TCRT a good stock to buy?

13F Pro's AI-powered analysis of Alaunos Therapeutics, Inc. (TCRT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TCRT are available on the TCRT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TCRT is classified as a small company.

Which hedge funds own TCRT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TCRT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Alaunos Therapeutics, Inc.'s investment landscape.